Synthesis and biological evaluation of 1,6-bis-triazole-2,3,4-tri-O-benzyl-α-d-glucopyranosides as a novel α-glucosidase inhibitor in the treatment of Type 2 diabetes

Bioorg Med Chem Lett. 2021 Oct 15:50:128331. doi: 10.1016/j.bmcl.2021.128331. Epub 2021 Aug 19.

Abstract

A novel series of 1,6-bis-triazole-benzyl-α-glucoside derivatives (7a-7ee) were designed, synthesized and evaluated for inhibitory activity against α-glucosidase. Most of the synthesized compounds exhibited good activity with IC50 ranging from 3.73 µM to 53.34 µM and are more potent than the standard drug acarbose (IC50 = 146.25 ± 0.40 µM). SARs study showed the ester and menthol moiety play an important role in the inhibitory activity. The molecular docking model of the potent compounds 7f, 7z, 7cc and 7dd showed good binding energy and interacts well with amino acid residues around the active site of the enzyme, which confirmed the in vitro activity results.

Keywords: Bis-triazole glucoside; Sugar; Type 2 diabetes mellitus; α-glucosidase inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Glucans / pharmacology*
  • Glycoside Hydrolase Inhibitors / pharmacology*
  • Humans
  • Hypoglycemic Agents / chemical synthesis*
  • Hypoglycemic Agents / pharmacology*
  • Models, Molecular
  • Molecular Docking Simulation
  • Molecular Structure
  • Protein Binding
  • Protein Conformation
  • alpha-Glucosidases / chemistry
  • alpha-Glucosidases / metabolism

Substances

  • Glucans
  • Glycoside Hydrolase Inhibitors
  • Hypoglycemic Agents
  • alpha-Glucosidases